Amphion creates, operates and finances life science and technology companies in partnership with corporations, governments, universities and entrepreneurs.
Collectively, the Management Team has created and developed more than 30 technology-driven companies in the information technology, physical and life science industries. Throughout its history the team has maintained significant involvement with many of the companies it has helped to create even after they have become public, including Celgene, MediSense, SEQUUS, and Quidel. The Management Team has been closely involved in the negotiation and sale of several of these companies with a combined total exit value (proceeds to shareholders) in excess of $1.6 billion.
In all the cases mentioned above, the company in question achieved significant revenue and in most cases profitability as well. For example, Celgene has revenue in excess of $377 million a year and is profitable. At the time of its sale to Abbott Labs, MediSense had revenue in excess of $174 million a year and was profitable.
For over 20 years, the Management Team has successfully raised over $230 million for principal investing activities and assisted its investee companies in raising over $500 million in both private and public transactions. The aggregate net increase in total equity value over this period in all such companies amounted to over $20 billion. Historically, the Management Team has achieved success in the life science sector through the team's company-building and value-creation skills, and control of overhead and headcount.
All companies created by the Management Team in this sector either remain successful public companies today (as measured by market capitalization and profitability), or were successfully sold to large pharmaceutical or technology companies. These life science companies include three Nasdaq listed companies; Celgene, Quidel Corportation, and La Jolla. In addition, Vortech to Kodak in 1993, Medisense to Abbott in 1996, and Sequus to Alza in 1998.
As an example, Celgene, Inc. is now one of the top ten biopharmaceutical companies, focused on the discovery, development and commercialization of drugs for the treatment of cancer and immunological disorders. The company has a market capitalization of over US $12 billion. Amphion’s management co-founded the company and have been actively involved in the company since it was founded. Richard Morgan was at one point CEO of Celgene and remains to this day a member of the Executive Committee of the Board.